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Background: Dengue is a major public health problem in many tropical and sub-tropical countries. Vascular leakage
and shock are identified as the major causes of deaths in patients with severe dengue. Studies have suggested the
potential role of Fc gamma receptors I (FcγRI) in the pathogenesis of dengue. We hypothesized that the circulating
level of Fcγ receptor I could potentially be used as an indicator in assisting early diagnosis of severe dengue.
Results: A selected cohort of 66 dengue patients including 42 dengue with signs of vascular leakage, and 24 dengue
without signs of vascular leakage were identified and were afterwards referred to as ‘cases’ and ‘controls’ respectively.
Thirty seven normal healthy controls were also recruited in this study. The circulating level of FcγRI was quantified from
the serum using enzyme-link immunosorbent assay (ELISA). The levels of FcγRI in both groups of patients with and
without vascular leakage were found to be significantly higher than the normal healthy controls (P < 0.001). However,
there was no significant difference found between patients with vascular leakage and those without vascular leakage
(p = 0.777).
Conclusion: We suggest that FcγRI is not associated with the vascular leakage in dengue. However, further studies are
necessary to delineate the role of FcγRI in antibody-dependent enhancement (ADE) mechanism.
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Dengue is caused by infection with one of the fours
related but antigenically distinct serotypes namely,
DENV-1, DENV-2, DENV-3, and DENV-4. Globally,
dengue infections have risen from less than 1,000 cases
in 1955 to almost 1,000,000 cases in 2007. Approximately
2.5 billion infected individuals live in endemic areas, of
which 50 million individuals are infected annually [1].
Dengue cases in Malaysia have risen dramatically, with
approximately 6,500 cases in 1995, to more than 49,000
cases in 2007 [2]. Dengue virus (DENV) infection
causes a spectrum of clinical manifestations, ranging* Correspondence: hoh.boonpeng@gmail.com
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article, unless otherwise stated.from asymptomatic, undifferentiated fever, dengue fever
(DF) to a more severe form of syndrome - dengue haem-
orrhagic fever (DHF), characterized by plasma leakage and
haemorrhage, representing a life-threatening complication
[3,4].
The severe form of dengue contributes approximately
5 - 10% of all reported cases, and could be lethal if it is
not treated properly [5,6]. Secondary infection is identi-
fied as a predominant risk factor leading to the severe
manifestation [7-9]. This can be explained partly by the
hypothesis called “antibody-dependent enhancement”
(ADE) mechanism in the host, which occurs when the
neutralizing antibody generated during the first immune
response binds to the DENV with different serotype during
secondary infection but not being able to neutralize it. The
DENV then unites with the heterotypic antibody, forming
the virus-immunoglobulin complex and enters the host
cells via Fc receptors. Subsequently, viral replicationMed Central. This is an Open Access article distributed under the terms of the
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storm” cascade, which eventually directs the alteration
of complement pathway, leading to the activation of
inflammatory signalling cascade and further resulting
in vascular leakage [11,12].
The Fc receptor is the principle component in ADE. It
is an important immunoglobulin receptor that involves
in regulating normal and pathological immunity [13]. The
IgG receptors (FcγR) is the largest family of Fc receptor, en-
coding two low-affinity receptor groups, FCGR2 and
FCGR3; and a unique high-affinity receptor, FCGR1 [14]. It
was believed that FCGR1 mediated the phagocytosis that is
involved in the removal of antibody-opsonized DENV [15].
Early detection of shock and other complications may
reduce the morbidity and mortality of severe dengue [1].
Although intensive efforts have been made to study the
earlier clinical pathophysiology of dengue by identifying
the potential cause of DHF, the appropriate strategy for
early detection and prediction on which patients would
progress to dengue hemorrhagic fever (DHF) has not
been established yet [16]. Given the potential role of
FcγRI in ADE, we hypothesized that it could possibly be
used as an indicator in assisting the early diagnosis of
dengue patients developing vascular leakage. Therefore in
this study, we attempted to evaluate circulating FcγRI levels
of dengue patients with vascular leakage versus without
vascular leakage, presumably that the circulating FcγRI
shaded from the cell surface in the course of infection.
Results and discussion
Of the 95 dengue patients recruited, 29 were excluded
from further analysis due to: (i) the negative results in
both IgM and IgG serology tests; and (ii) the presence of
co-infection. Sixty-six (66) dengue subjects (41 males
and 25 females, of which 53 were Malays, 5 Chinese and
8 Indians), and 37 normal subjects (11 males and 26
females, of which 28 were Malays, 3 Chinese and 6
Indians) remained for the analysis (Table 1). All subjects
were presented with fever greater than 37°C, accompanied
by two or more of the following manifestations: abdominal
pain, headache, vomiting, hepatomegaly, leukopenia or
thrombocytopenia. Dengue causes a wide range of clinical
manifestations. Therefore, although the subjects were clin-
ically classified as uncomplicated DF, DF(WS), and SD, the
focus was made on a single trait known to be the hallmark
symptom of dengue hemorrhagic fever - vascular leakage,
with the notion that the severe form of dengue can be pre-
vented by preventing the vascular leakage of the patients.
The samples were categorized as “cases” when they
presented any signs of vascular leakage; and “control”
for those without signs of vascular leakage. Dengue with
signs of vascular leakage can be defined when either pa-
tient has (i) a significant increased level of hematocrit
(HCT) (20% above the baseline measurement, or >46% asindicated by the Ministry of Health Malaysia [1,17]; or,
(ii) the presence of pleural effusion, and/or ascites. In
clinical settings, HCT level has been commonly used as
an indicator for vascular leakage [12]. Based on our
evaluation of the sample classifications, apparently 92.4%
of the cases/controls classifications were in accordance
with the clinical diagnosis, except for five subjects. All
the five subjects were clinically diagnosed as DF, yet,
there was a marked increment of HCT. Therefore, it was
categorized as “cases”.
The maximum HCT level between the cases and con-
trols were significantly different (P < 0.001), supporting
a well sample classification between these groups (Table 1).
No significant difference was observed between the den-
gue groups by duration of illness (p = 0.856), thus we elim-
inated this as a potential confounding factor for the
disease severity in this study.
The FcγRI levels were compared between the cases
and controls, and then with the normal healthy controls
(denoted as NC) (Figure 1). The FcγRI protein level was
significantly higher (p < 0.001) in the control group com-
pared to NC. It was also observed that the level of FcγRI
in cases group was significantly higher (p = 0.001) than
NC. However, there was no significant difference between
the cases and controls (p = 0.777) (Figure 1).
The mortality of dengue patients could have been im-
proved by early detection of dengue infection followed
by intensive treatments of the patient [18]. However, one
of the major challenges to the clinicians is to accurately
identify patients who potentially develop vascular leakage,
a hallmark symptom prior to the development of a severe
form of dengue. Therefore, identification of biomarkers
for early detection of vascular leakage in dengue is crucial
for effective management of the dengue patients. To date,
although several diagnostic methods are available for den-
gue diagnosis [19-22], none could accurately predict the
propensity for dengue-infected patients to progress into
vascular leakage.
The immunoglobulin FcRs play a critical role in the
immune defense system by binding the Fc portions of
antibodies and providing a link between humoral and
cellular immune response [23]. FcγRI is an activating
receptor that recruits the gamma subunit with immune-
receptor tyrosine-based activating motif to phosphorylate
kinases that signals for phagocytosis [24], pro-inflammatory
responses [13], protection from bacteria [25], viruses [26]
and helps in the removal of antibody-opsonized DENV
[15]. Over the past decade, research in the field of Fc-
receptors biology and their role during various phases of
an immune response has been well established [27-29].
But for the first time, we presented that there was signifi-
cant elevation of circulating FcγRI, presumably shaded
from the cell surface in course of the disease, observed in
patients with dengue. Our results demonstrated that
Table 1 Demographic data with average duration of illness and laboratory parameters of normal healthy subjects,
controls and cases
Demographics **p value
Normal (healthy) Control Case
Number of patients 37 24 42 NA
Gender Female 26 7 18 0.003
Male 11 17 24
Age (years) 11 – 20 1 4 11 0.677
21 – 30 27 12 15
31 – 40 7 3 9
41 – 50 1 3 6
51 – 60 1 1 1
Average duration of illness (DOI) (days) NA 5 (3 – 7) 5 (1 – 7) 0.856
Body temperature, mean (°C) NA 38.5 (37.0 – 40.0) 38.1 (37.0 – 40.6) NA
Max Hct, mean Female NA 38.0 (35.7 – 39.9) 42.9 (26.5 – 50.0) <0.001
Male NA 42.7 (33.8 – 45.7) 48.7 (40.0 – 55.5)
*NA, not applicable; **The indicated P value in the gender was calculated for both males and females in normal, control and case groups, indicating a nonrandom
gender distribution in the groups; age refers to the distribution of normal, control and case groups (P<0.05).
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supporting evidences of its involvement in the events of
immune responses during dengue viral infection [15].
In this study we also observed that the dengue patients
who showed signs of vascular leakage; although not sig-
nificant, on average, demonstrated a relatively lower FcγRI
(Figure 1). Animal model study suggested that FcγRI defi-
cient may lead to impaired phagocytosis of the immune
complex function, hence resulting into the elevation of
antibody responses [13]. This leads us to postulate that
the reduced of FcγRI level in patients with vascular leak-
age causes elevation of antibody level, therefore increasesFigure 1 Serum level of FcγRI measured by ELISA for normal
healthy controls, controls and cases. Asterisks indicate p value for
normal healthy controls, controls and cases. P value is statistically
significant (p < 0.001) in the control group compared to normal
healthy controls. No statistically significant difference between cases
and controls (P = 0.777).the number of antibody-forming cells, which in turn in-
creases the bridging of infections of DENV particles and
FcR on cell surfaces. Consequently, it also increases the
number of the infected cell. The reason why it is not sig-
nificant between ‘cases’ and ‘controls’ is unclear though,
and warrants further investigation in the future. We real-
ized that the day of which the samples were collected from
the day of onset illness (DOI), a potential confounding
factors to this finding. Hence, we repeated the analysis by
including the samples that was only collected within 4th –
7th duration of illness, and found no significant difference
of FcγRI level (Figure 2).Figure 2 Comparison of the circulating FcγRI level of the controls
and cases using ELISA, representing the repeat analysis that
involves samples collected within 4th – 7th day of duration of
illness. No statistical significance was observed between the two
categories (P = 0.062).
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trols in this study could be associated to two downsides
of the study, namely; (i) the sample size recruited; and
(ii) the emphasis given only to subjects with vascular
leakage may possibly lead to false negative finding.
Conclusion
Our study shows a significant difference of FcγRI levels
between dengue patients and normal healthy controls,
but not between dengue patients with or without vascu-
lar leakage. Further understanding on the role of FcγRI
in the mechanism of ADE upon FcγR mediated phago-
cytosis is crucial for the understanding of immunity and
pathogenesis of vascular leakage, to further assisting in
refining the vaccine development [30] and also the
development of the biomarker for vascular leakage of
dengue.
Methods
Ethics statement and study population
This study was reviewed and approved in accordance with
the Ethical Committee of Universiti Teknologi MARA
and Ministry of Health Malaysia, for the study of host
genetics of dengue (Ministry of Health: NMRR-09-1128-
4211; Universiti Teknologi MARA: 600-RMI (5/1/6)).
Ninety-five (95) adult patients clinically diagnosed with
dengue were recruited in this study. Diagnosis of dengue
were confirmed by performing commercially available
Dengue specific capture Enzyme-Linked Immunosorbent
Assay kit (ELISA) IgG and IgM tests (PanBio, Australia)
[31,32] to all 95 collected serum samples. Informed and
written consent was obtained from the patients. Three
millilitres (3 ml) of patients’ peripheral blood were col-
lected. Patients who were diagnosed to be co-infected with
other pathogens, or were negative for both IgG and IgM,
were excluded from the study. All patients were admitted
to the medical ward in Hospital Sungai Buloh during the
year of 2010 to 2012. Subjects were clinically diag-
nosed as dengue fever (DF), dengue fever with warning
sign [DF(WS)], or severe dengue (SD) by the clinicians
from the hospital, following 2009 World Health
Organization (WHO) case definition [1]. Demographic
characteristics (i.e. age, gender and race) and clinical
manifestations (i.e. day of fever, body temperature, bleeding
manifestation, pleural effusion, ascites and abdominal pain)
were gathered with routine hematological and biochemical
laboratory test findings (i.e. full blood count, liver function
test).
Additional blood samples were collected from 37
healthy volunteers to determine serum FcγRI antibody
levels in the population, and these samples serve as nor-
mal healthy control subjects. Healthy volunteers were
characterized as have not been infected with dengue
that is the absence of any dengue antibody (IgM and/orIgG). Healthy volunteers were matched to patients ac-
cording to age, gender and race that were selected from
the community as a normal group.
Quantification of FcγRI
Quantification of FcγRI level was carried out in duplicates
on the serum samples using FcγRI pre-coated ELISA
plates (i-DNA Technologies, Singapore). Standards and
100 μl of diluted serum sample (1:100 dilution) were
added to their respective wells. The microtiter plate was
pre-coated with antibody specific to FcγRI and the colour
change was measured by using spectrophotometer.
The concentration of FcγRI in the samples was then
determined by comparing the optical density (O.D.) of
the samples to the standard curve.
Statistical analysis
Comparisons of the mean values within groups were
carried out using one-way ANOVA, followed by Sidak
post-test to identify the differences. Data analysis was
carried out using SPSS for Windows version 20.0 (SPSS
Inc. Chicago, IL, USA). P value of less than 0.05 was
considered to be significant for all tests performed.
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